In a report released today, Laura Chico from Wedbush maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with a price target of $38.00. The company’s shares closed yesterday at $24.93.
According to TipRanks, Chico is a 3-star analyst with an average return of 2.3% and a 45.48% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Pharvaris, and Ultragenyx Pharmaceutical.
Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $43.00.
Based on Dianthus Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $3.66 million. In comparison, last year the company had a net profit of $19.53 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dianthus Therapeutics (DNTH) Company Description:
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
Read More on DNTH:
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
- Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus price target raised to $51 from $34 at Raymond James
- Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
